Ulrich Emde

USPTO Granted Patents = 18 (Patent Applications = 5)

CIPO Patents = 8

EPO Patents = 13 (Patent Applications = 11)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 36(Granted Patents)

Company Filing History:

Merck Patent Gesellschaft MIT Beschrankter Haftung

Years Active: 2011-2021

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11065253 - Arylquinazolines (2021-07-20),

2. 10383874 - Arylquinazolines (2019-08-20),

3. 10172859 - Arylquinazolines (2019-01-08),

4. 9732094 - Arylquinazolines (2017-08-15),

5. 9187469 - Morpholinylbenzotriazines for use in cancer therapy (2015-11-17),

6. 8895559 - Quinoxalines derivatives and pharmaceutical compositions and kits (2014-11-25),

7. 8802866 - Pyridinylimidazolone derivatives for the inhibition of PI3 kinases (2014-08-12),

8. 8741896 - Pyrazolopyrimidine derivatives (2014-06-03),

9. 8431602 - Beta-amino acid derivatives for treatment of diabetes (2013-04-30),

10. 8383838 - 5-oxo-2,3,4,5-tetrahydro-benzo[b]oxepine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxepine-4-carboxylic acid amides for treatment and prevention of diabetes typ 1 and 2 (2013-02-26),

11. 8278454 - Process for preparing tetrahydroquinoline derivatives (2012-10-02),

12. 8236824 - N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators (2012-08-07),

13. 8207345 - Tetrahydroquinolines for use as modulators of the mitotic motor protein Eg5 (2012-06-26),

14. 8198452 - Polymorphic forms and process (2012-06-12),

15. 7915416 - Tetrahydroquinolines (2011-03-29),

Title: Innovations of Ulrich Emde in Protein Kinase Inhibition

Introduction

Ulrich Emde, a prominent inventor based in Darmstadt, Germany, has made significant contributions to the field of biotechnology with 18 patents to his name. His research primarily focuses on novel compounds that have the potential to enhance cancer treatment efficacy. Through his innovative work, he aims to advance the understanding of drug interactions and cancer cell sensitization.

Latest Patents

Among Ulrich Emde's most notable patents are the developments surrounding Arylquinazolines. These innovative compounds demonstrate a unique formula that can inhibit serine-threonine protein kinases, which play a crucial role in various cellular processes. Emde's research emphasizes the capability of these compounds to sensitize cancer cells to anticancer agents and ionizing radiation, addressing a significant challenge in cancer therapy.

Career Highlights

Throughout his career, Ulrich has worked with esteemed organizations, including Merck Patent GmbH and Merck Patent Gesellschaft mit beschränkter Haftung. His contributions to these companies have established him as a key figure in the realm of patentable innovations within the biopharmaceutical industry.

Collaborations

Ulrich Emde's journey in the field of innovation has seen him collaborate with talented professionals, including Hans-Peter Buchstaller and Kai Schiemann. These collaborations have fostered a dynamic exchange of ideas, further propelling the development of cutting-edge research and patent applications.

Conclusion

Ulrich Emde's extensive work and patent portfolio underscore his significant impact on medical research and cancer treatment solutions. His innovative approach towards Arylquinazolines and their application in inhibiting protein kinases showcases the collaborative spirit and ingenuity prevalent in the field of biotechnology. As he continues to push boundaries, Emde's contributions remain vital to advancing therapeutic strategies for cancer treatment.

This text is generated by artificial intelligence and may not be accurate.